Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Abbott Laboratories ABT reported first-quarter 2025 adjusted earnings per share (EPS) of $1.09, which beat the Zacks ...

CEO Robert Ford noted that Abbott has 90 manufacturing locations worldwide, with plants close to customers, redundancy, and ...

Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and ...

Abbott Laboratories reports strong Q1 2025 results with 8% organic growth, double-digit EPS gains, and robust Medical Devices performance.

The Volt PFA System builds upon Abbott's leading electrophysiology (EP) portfolio by providing a single-catheter PFA approach, improving workflow by allowing for mapping, pacing, and ablating with a ...

Abbott is joining the worldwide race to make ... making them more efficient,” the chief medical officer of Abbott’s electrophysiology business, Christopher Piorkowski, said in a statement ...

Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments. The healthcare products ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...